Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:BLTEOTCMKTS:CURLFNASDAQ:NAMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$28.38+1.5%$23.35$16.50▼$28.68$2.47BN/A57,306 shs5,569 shsBLTEBelite Bio$59.68-7.1%$60.82$43.70▼$86.53$1.90B-1.4448,469 shs85,471 shsCURLFCuraleaf$0.88+3.4%$0.86$0.68▼$4.51$583.60M0.83649,426 shs223,057 shsNAMSNewAmsterdam Pharma$20.14+3.2%$17.78$14.06▼$27.29$2.26B-0.03661,297 shs1.00 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-1.13%+10.34%+9.00%+40.34%+2,796,999,900.00%BLTEBelite Bio-1.62%-2.16%+4.02%+1.63%+31.90%CURLFCuraleaf-1.05%-2.96%-8.49%-15.74%-81.00%NAMSNewAmsterdam Pharma+0.62%+10.66%+2.68%-18.03%+1.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/ABLTEBelite Bio2.156 of 5 stars3.53.00.00.01.80.80.6CURLFCuraleaf2.825 of 5 stars3.54.00.00.02.80.01.3NAMSNewAmsterdam Pharma2.6802 of 5 stars3.51.00.00.02.75.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/ABLTEBelite Bio 3.00Buy$96.6761.97% UpsideCURLFCuraleaf 3.00Buy$6.25610.23% UpsideNAMSNewAmsterdam Pharma 3.00Buy$42.86112.80% UpsideCurrent Analyst Ratings BreakdownLatest CURLF, AAPG, NAMS, and BLTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025NAMSNewAmsterdam PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$42.005/15/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.005/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $40.004/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/27/2025AAPGAscentage Pharma Group InternationalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight3/26/2025BLTEBelite BioBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.003/18/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/18/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$980.65M2.52N/AN/AN/A∞BLTEBelite BioN/AN/AN/AN/A$3.28 per shareN/ACURLFCuraleaf$1.35B0.43$0.09 per share9.57$1.64 per share0.54NAMSNewAmsterdam Pharma$47.14M47.97N/AN/A$3.50 per share5.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group InternationalN/AN/A0.00∞N/AN/AN/AN/AN/ABLTEBelite Bio-$31.63M-$1.36N/AN/AN/AN/A-31.94%-30.73%8/8/2025 (Estimated)CURLFCuraleaf-$281.20M-$0.31N/AN/AN/A-14.82%-13.67%-4.58%N/ANAMSNewAmsterdam Pharma-$176.94M-$1.88N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)Latest CURLF, AAPG, NAMS, and BLTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CURLFCuraleaf-$0.07-$0.07N/A-$0.08N/AN/A5/8/2025Q1 2025NAMSNewAmsterdam Pharma-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million3/17/2025Q4 2024BLTEBelite Bio-$0.30-$0.32-$0.02-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/ACURLFCuraleafN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group InternationalN/AN/AN/ABLTEBelite BioN/A30.7330.73CURLFCuraleaf0.851.110.51NAMSNewAmsterdam PharmaN/A10.6110.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/ABLTEBelite Bio0.53%CURLFCuraleaf0.03%NAMSNewAmsterdam Pharma89.89%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/ABLTEBelite Bio13.29%CURLFCuraleafN/ANAMSNewAmsterdam Pharma20.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.11 millionN/AN/ABLTEBelite Bio1031.84 million27.61 millionNot OptionableCURLFCuraleaf5,600663.18 millionN/ANot OptionableNAMSNewAmsterdam Pharma4112.27 million74.37 millionOptionableCURLF, AAPG, NAMS, and BLTE HeadlinesRecent News About These CompaniesNewAmsterdam Pharma to Host R&D Day on June 11, 2025June 5 at 8:00 AM | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated at Cantor FitzgeraldJune 5 at 3:51 AM | americanbankingnews.comShort Interest in NewAmsterdam Pharma (NASDAQ:NAMS) Grows By 23.6%June 4 at 6:08 PM | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 7.2% - Here's WhyJune 4 at 2:36 PM | marketbeat.comCantor Fitzgerald Initiates Coverage on NewAmsterdam Pharma (NASDAQ:NAMS)June 4 at 8:16 AM | marketbeat.comNewAmsterdam Pharma (NAMS) Receives Overweight Rating from Cantor Fitzgerald | NAMS Stock NewsJune 4 at 6:27 AM | gurufocus.comBuy Rating Affirmed for NewAmsterdam Pharma: Obicetrapib’s Promising Clinical Profile and Market Potential HighlightedJune 3 at 8:33 PM | tipranks.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $6.52 Million Stake in NewAmsterdam Pharma (NASDAQ:NAMS)June 2, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Holdings Trimmed by Two Sigma Investments LPJune 1, 2025 | marketbeat.comNorthern Trust Corp Takes $556,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS)June 1, 2025 | marketbeat.comWellington Management Group LLP Acquires 2,222,900 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)May 31, 2025 | marketbeat.com28,041 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Acquired by Voloridge Investment Management LLCMay 31, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Holdings Trimmed by Two Sigma Advisers LPMay 31, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Rating Upgraded by Wall Street ZenMay 31, 2025 | americanbankingnews.comNewAmsterdam Pharma (NASDAQ:NAMS) Rating Increased to Hold at Wall Street ZenMay 31, 2025 | marketbeat.comBrokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.00May 28, 2025 | americanbankingnews.comNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in JuneMay 27, 2025 | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by Millennium Management LLCMay 26, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Recommendation of "Buy" by AnalystsMay 26, 2025 | marketbeat.comNewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular marketMay 24, 2025 | investing.com35,657 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by BNP Paribas Financial MarketsMay 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCURLF, AAPG, NAMS, and BLTE Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$28.38 +0.41 (+1.47%) As of 03:59 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Belite Bio NASDAQ:BLTE$59.68 -4.54 (-7.07%) Closing price 04:00 PM EasternExtended Trading$59.28 -0.40 (-0.67%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Curaleaf OTCMKTS:CURLF$0.88 +0.03 (+3.41%) As of 03:59 PM EasternCuraleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.NewAmsterdam Pharma NASDAQ:NAMS$20.14 +0.63 (+3.23%) Closing price 04:00 PM EasternExtended Trading$20.14 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
